High investor density at the Pitch Day hosted by the IZB
December 2019
© IZB
Investors at the 5th Munich Life Science Pitch Day 2019 (f.l.t.r.):
Dr. Joachim Vogt, AbbVie Inc., Fis Emri, Saverna Therapeutics, Andreas Huber, Bayern Kapital, Dr. Holger Reithinger, Forbion Capital Partners, Annegret de Baey-Diepolder, Seventure Partners, Dr. Marianne Mertens, Wellington Partners Advisory AG, Dr. Joachim Rothe, Life Sciences Partners, Thomas Möller, BioMedPartners AG, Laurent Jacqueroud, Kurma Partners SA, Dr. Ioannis Sapountzis, Boehringer Ingelheim, Dr. Bernd Goergen, HTGF, Christoph Kocher, Gimv, Daniel Parera, TVM Life Science Management GmbH, Dr. Marie Asano, HTGF, Dr. Lena Krzyzak, HTGF, Dr. Daniel Dillinger, Redalpine Venture Partners AG, Dr. Benedikt Luhmann, VI Partners AG, Cédric Barra, Occident Group AG, Dr. Peter Neubeck, Kurma Partners SA
Twelve project teams presented their top-class research to 25 VCs
Together with Bayer AG and Boehringer Ingelheim as strategic partners, the High-Tech Gründerfonds (HTGF) and the Innovation and Start-up Center Biotechnology (IZB) in Martinsried near Munich organized the “5th Munich Life Science Pitch Day” held on July 11, 2019 at the Faculty Club of the IZB. Twenty-nine project teams applied for the Pitch Day and twelve selected start-ups got the chance to present themselves to 25 investors. Dr. Lena Krzyzak, Senior Investment Manager of HTGF, moderated the event. The opening speeches were held by Dr. Peter Hanns Zobel (Managing Director of the IZB), Prof. Stefan Jaroch (Head of Strategic Technology Partnerships, Bayer AG), Dr. Marianne Mertens (Principal, Wellington Partners Life Science Venture Capital), Dr. Lena Krzyzak (Senior Investment Manager, High-Tech Gründerfonds) and Dr. Ioannis Sapountzis (Global Head BD&L, Boehringer Ingelheim).
© IZB
Partners of the 5th Munich Life Science Pitch Day at the IZB (f.l.t.r.):
Dr. Peter Hanns Zobel, Managing Director, IZB, Prof. Dr. Stefan Jaroch, Head of Strategic Technology Partnerships, Bayer AG, Dr. Lena Krzyzak, Senior Investment Manager, High-Tech Gründerfonds, Dr. Ioannis Sapountzis, Global Head BD&L, Boehringer Ingelheim
© IZB
Project teams at the 5th Munich Life Science Pitch Day 2019
(f.l.t.r.): Dr. Kamal Azzaoui, Saverna Therapeutics; Prof. Dr. Matthias Mack, ImmuCon; Dr. Tim Horlacher, SiBreaX; Dr. Marius Yildiz, Avergen; Dr. Jens Kelm, PreComb; Dr. Thomas Taapken, Bluehaven; Alexander Schueller, CellVita; Dr. Ing. Miriam Haerst, Kumovis; Prof. Dr. Eric Hesse, Sirana Pharma GmbH; Dr. Nadja Fenn, Opsyon; Dr. Cornelius Sobel, Actitrexx; Dr. Francisco Pan-Montojo, Jochen Rheinwald, both Glymipro
In his keynote speech, Dr. Daniel Vitt, CEO of Immunic, Inc., described the path from start-up to stockmarket company on NASDAQ in just three years. Top-calibre research ranging from the introduction of silicate nanoparticles as a new drug delivery system, a microRNA approach to the loss of bone mass and muscle function, the development of novel cancer therapeutics, humanized antibodies for the treatment of MS/SLE patients, and increased efficacy of medications in the context of organ transplants. Fifty-five guests attended the event.
